Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 123: 249-260, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28487067

ABSTRACT

BACKGROUND: Metabotropic glutamate receptor 4 (mGluR4) and dopamine D2 receptors are specifically expressed within the indirect pathway neurons of the striato-pallidal-subthalamic pathway. This unique expression profile suggests that mGluR4 and D2 receptors may play a cooperative role in the regulation and inhibitory control of behaviour. We investigated this possibility by testing the effects of a functionally-characterised positive allosteric mGluR4 modulator, 4-((E)-styryl)-pyrimidin-2-ylamine (Cpd11), both alone and in combination with the D2 receptor antagonist eticlopride, on two distinct forms of impulsivity. METHODS: Rats were trained on the five-choice serial reaction time task (5-CSRTT) of sustained visual attention and segregated according to low, mid, and high levels of motor impulsivity (LI, MI and HI, respectively), with unscreened rats used as an additional control group. A separate group of rats was trained on a delay discounting task (DDT) to assess choice impulsivity. RESULTS: Systemic administration of Cpd11 dose-dependently increased motor impulsivity and impaired attentional accuracy on the 5-CSRTT in all groups tested. Eticlopride selectively attenuated the increase in impulsivity induced by Cpd11, but not the accompanying attentional impairment, at doses that had no significant effect on behavioural performance when administered alone. Cpd11 also decreased choice impulsivity on the DDT (i.e. increased preference for the large, delayed reward) and decreased locomotor activity. CONCLUSIONS: These findings demonstrate that mGluR4s, in conjunction with D2 receptors, affect motor- and choice-based measures of impulsivity, and therefore may be novel targets to modulate impulsive behaviour associated with a number of neuropsychiatric syndromes.


Subject(s)
Dopamine D2 Receptor Antagonists/pharmacology , Excitatory Amino Acid Agonists/pharmacology , Impulsive Behavior/drug effects , Motor Activity/drug effects , Pyrimidines/pharmacology , Salicylamides/pharmacology , Styrenes/pharmacology , Animals , Attention/drug effects , Attention/physiology , Cyclic AMP/metabolism , Delay Discounting/drug effects , Delay Discounting/physiology , Dopamine D2 Receptor Antagonists/blood , Dose-Response Relationship, Drug , Excitatory Amino Acid Agonists/blood , Excitatory Amino Acid Agonists/cerebrospinal fluid , Impulsive Behavior/physiology , Male , Motor Activity/physiology , Psychotropic Drugs/pharmacology , Pyrimidines/blood , Pyrimidines/cerebrospinal fluid , Rats , Receptors, Dopamine D2/metabolism , Receptors, Metabotropic Glutamate/agonists , Receptors, Metabotropic Glutamate/metabolism , Salicylamides/blood , Styrenes/blood , Styrenes/cerebrospinal fluid , Visual Perception/drug effects , Visual Perception/physiology
2.
Neuropsychopharmacology ; 38(10): 2019-26, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23615666

ABSTRACT

The glutamatergic neurotransmission system and the N-methyl-D-aspartate receptor (NMDAR) have been implicated in smoking and alcohol consumption behavior. Preclinical studies have demonstrated that nicotine and ethanol influence NMDAR functionality, which may have a role in tendencies to consume these substances. Nonetheless, little is known about concentrations of NMDAR coagonists in the cerebrospinal fluid (CSF) and plasma of individuals who smoke or consume alcohol. Glycine and L- and D-stereoisomers of alanine, serine, and proline were therefore measured using ultra-high-performance liquid chromatography-tandem mass spectrometry in 403 healthy subjects. Nicotine and alcohol consumption were quantified using questionnaires. Possible differences in NMDAR coagonist concentrations in plasma and CSF were investigated using ANCOVA with age, body mass index, and storage duration as covariates. The significance threshold was Bonferroni corrected (α=0.00625). Compared with non-smokers, smokers displayed lower levels of D-proline in plasma (p=0.0027, Cohen's d=-0.41) and D-proline in CSF (p=0.0026, Cohen's d=-0.43). D-Serine in CSF was higher in smokers than in non-smokers (p=0.0052, Cohen's d=0.41). After subdividing participants based on smoking quantity, dose-dependent decreases were demonstrated in smokers for D-proline in plasma (F=5.65, p=0.0039) and D-proline in CSF (F=5.20, p=0.0060). No differences in NMDAR coagonist levels between alcohol consumption groups were detected. To our knowledge, this is the first report to implicate D-amino acids in smoking behavior of humans. Whether such concentration differences lie at the root of or result from smoking habits may be addressed in prospective studies.


Subject(s)
Alcohol Drinking/blood , Alcohol Drinking/cerebrospinal fluid , Excitatory Amino Acid Agonists/blood , Excitatory Amino Acid Agonists/cerebrospinal fluid , Smoking/blood , Smoking/cerebrospinal fluid , Adult , Alanine/blood , Alanine/cerebrospinal fluid , Female , Glycine/blood , Glycine/cerebrospinal fluid , Humans , Male , Proline/blood , Proline/cerebrospinal fluid , Self Report , Serine/blood , Serine/cerebrospinal fluid , Stereoisomerism
3.
Neuropsychopharmacology ; 38(5): 743-52, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23299933

ABSTRACT

The NMDA-receptor antagonist ketamine has proven efficient in reducing symptoms of suicidality, although the mechanisms explaining this effect have not been detailed in psychiatric patients. Recent evidence points towards a low-grade inflammation in brains of suicide victims. Inflammation leads to production of quinolinic acid (QUIN) and kynurenic acid (KYNA), an agonist and antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor, respectively. We here measured QUIN and KYNA in the cerebrospinal fluid (CSF) of 64 medication-free suicide attempters and 36 controls, using gas chromatography mass spectrometry and high-performance liquid chromatography. We assessed the patients clinically using the Suicide Intent Scale and the Montgomery-Asberg Depression Rating Scale (MADRS). We found that QUIN, but not KYNA, was significantly elevated in the CSF of suicide attempters (P<0.001). As predicted, the increase in QUIN was associated with higher levels of CSF interleukin-6. Moreover, QUIN levels correlated with the total scores on Suicide Intent Scale. There was a significant decrease of QUIN in patients who came for follow-up lumbar punctures within 6 months after the suicide attempt. In summary, we here present clinical evidence of increased QUIN in the CSF of suicide attempters. An increased QUIN/KYNA quotient speaks in favor of an overall NMDA-receptor stimulation. The correlation between QUIN and the Suicide Intent Scale indicates that changes in glutamatergic neurotransmission could be specifically linked to suicidality. Our findings have important implications for the detection and specific treatment of suicidal patients, and might explain the observed remedial effects of ketamine.


Subject(s)
Encephalitis/cerebrospinal fluid , Encephalitis/psychology , Excitatory Amino Acid Agonists/cerebrospinal fluid , Suicide/psychology , Adult , Aged , Excitatory Amino Acid Agonists/therapeutic use , Female , Follow-Up Studies , Humans , Interleukin-6/metabolism , Kynurenic Acid/cerebrospinal fluid , Kynurenine/cerebrospinal fluid , Male , Mental Disorders/complications , Mental Disorders/psychology , Middle Aged , Psychiatric Status Rating Scales , Quinolinic Acid/cerebrospinal fluid , Retrospective Studies , Somatosensory Disorders/complications , Spinal Puncture , Tritium/cerebrospinal fluid , Young Adult
4.
Drug Metab Dispos ; 33(9): 1373-81, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15980102

ABSTRACT

Metabolism and disposition of MGS0028 [(1R,2S,5S,6S)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid monohydrate], a potent group II metabotropic glutamate receptor agonist, were examined in three preclinical species (Sprague-Dawley rats, beagle dogs, and rhesus monkeys). In rats, MGS0028 was widely distributed and primarily excreted in urine as parent and as a single reductive metabolite, identified as the 4R-isomer MGS0034 [(1R,2S,4R,5S,6S)-2-amino-6-fluoro-4-hydroxybicyclo[3.1.0]-hexane-2,6-dicarboxylic acid]. MGS0028 had a low brain to plasma ratio at efficacious doses in rats and was eliminated more slowly in rat brain than in plasma. Exposure increased proportionally (1--10 mg/kg p.o.) in rats, with bioavailability>60% at all doses. However, bioavailability was only approximately 20% in monkeys, and MGS0034 was found in relatively high abundance in plasma. In dogs, oral bioavailability was >60%, and the metabolite was not detected. In vitro metabolism was examined in liver subcellular fractions (microsomes and cytosol) from rat, dog, monkey, and human. Reductive metabolism was observed in rat, monkey, and human liver cytosol incubations, but not in dog liver cytosol incubations. No metabolism of MGS0028 was detected in incubations with liver microsomes from any species. Similar to in vivo results, MGS0028 was reduced in cytosol stereospecifically to MGS0034. The rank order of in vitro metabolite formation (monkey >> rat approximately human >> dog) was in agreement with in vivo observations in rats, dogs, and monkeys. Based on the observation of species difference in reductive metabolism, rat and monkey were recommended to be the preclinical species for further characterization prior to testing in humans. Finally, allometric scaling predicts that human pharmacokinetic parameters would be acceptable for further development.


Subject(s)
Bridged Bicyclo Compounds/pharmacokinetics , Dicarboxylic Acids/pharmacokinetics , Excitatory Amino Acid Agonists/pharmacokinetics , Receptors, Metabotropic Glutamate/agonists , Animals , Bridged Bicyclo Compounds/blood , Bridged Bicyclo Compounds/cerebrospinal fluid , Bridged Bicyclo Compounds/urine , Carbon Radioisotopes , Cells, Cultured , Cerebellum/metabolism , Dicarboxylic Acids/blood , Dicarboxylic Acids/cerebrospinal fluid , Dicarboxylic Acids/urine , Dogs , Excitatory Amino Acid Agonists/blood , Excitatory Amino Acid Agonists/cerebrospinal fluid , Excitatory Amino Acid Agonists/urine , Feces/chemistry , Humans , Macaca mulatta , Male , Microsomes, Liver/metabolism , Protein Binding , Rats , Rats, Sprague-Dawley , Species Specificity , Telencephalon/metabolism , Tissue Distribution
5.
Behav Brain Res ; 73(1-2): 273-5, 1996.
Article in English | MEDLINE | ID: mdl-8788517

ABSTRACT

Serotonin activation of 5-HT2A receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate (NMDA). Using grease-gap recordings from an in vitro cortical wedge preparation we have examined whether agents which raise the concentration of intracellular Ca2+ mimic the facilitation. Perfusing A23187, cyclopiazonic acid or thapsigargin selectively facilitate the NMDA depolarization of cortical neurons in a concentration-dependent manner. Buffering intracellular Ca2+ by perfusing BAPTA-AM eliminates the serotonin, cyclopiazonic acid and thapsigargin induced facilitation. We conclude that a rise in intracellular Ca2+ is both necessary and sufficient to account for facilitating the NMDA depolarization following activation of 5-HT2A receptors.


Subject(s)
Calcium/metabolism , Excitatory Amino Acid Agonists/pharmacology , N-Methylaspartate/pharmacology , Receptors, Serotonin/metabolism , Animals , Calcimycin/pharmacology , Calcium-Transporting ATPases/antagonists & inhibitors , Cell Polarity/drug effects , Chelating Agents/pharmacology , Egtazic Acid/analogs & derivatives , Egtazic Acid/pharmacology , Enzyme Inhibitors/pharmacology , Excitatory Amino Acid Agonists/cerebrospinal fluid , In Vitro Techniques , Indoles/pharmacology , Ionophores/pharmacology , N-Methylaspartate/cerebrospinal fluid , Neurons/drug effects , Rats , Receptors, Serotonin/drug effects , Thapsigargin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...